Mar 112020
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– USA, WA – Silverback Therapeutics, a private biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC drug conjugates targeting previously inaccessible disease pathways, today announced the close of an oversubscribed $78.5 million Series B financing round led by U.S. Venture Partners (USVP) with participation from new investors including Nextech Invest Ltd., Hunt Investment Group, ...

Silverback Therapeutics adds Dr Jonathan Root and Dr Thilo Schroeder to Board along with raising $78m Series B financing led by USVP

From:: Silverback Therapeutics adds Dr Jonathan Root and Dr Thilo Schroeder to Board along with raising $78m Series B financing led by USVP

Sorry, the comment form is closed at this time.